Lifecore appoints Ryan Lake as CFO effective Sept 3; Morberg departs Sept 2

LIFECORE BIOMEDICAL, INC. DE

John Morberg steps down as CFO effective Sept 2, 2024; Ryan Lake succeeds him on Sept 3, 2024.
Lake receives $470K base salary, RSU for 262,500 shares, and PSU for up to 750,000 shares under Inducement Plan.
Lake previously served as CFO of Societal CDMO, leading its sale to CoreRx in April 2024.
Morberg's separation treated as termination without Cause after a Change in Control under his employment agreement.

item 3.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ryan D. Lake

Chief Financial Officer and Secretary

LFCR · LIFECORE BIOMEDICAL, INC. DE

Effective: 2024-09-03
Filed: August 29, 2024, 7:59 PM ET

On August 28, 2024, the Company appointed Ryan D. Lake as the Company’s Chief Financial Officer and Secretary, effective September 3, 2024

Departed

John D. Morberg

Chief Financial Officer and Secretary

LFCR · LIFECORE BIOMEDICAL, INC. DE

Effective: 2024-09-02
Successor: Ryan D. Lake
Filed: August 29, 2024, 7:59 PM ET

Mr. Morberg's separation will be treated as a termination by the Company without Cause subsequent to a Change in Control under that certain Executive Employment Agreement (the "Morberg Employment Agreement"), dated January 19, 2021, between the Company and Mr. Morberg

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ryan D. Lake was appointed as Chief Financial Officer and Secretary at LIFECORE BIOMEDICAL, INC. DE.

Action: appointed
Role: Chief Financial Officer and Secretary

Exact text from the filing

On August 28, 2024, the Company appointed Ryan D. Lake as the Company’s Chief Financial Officer and Secretary, effective September 3, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

John D. Morberg departed as Chief Financial Officer and Secretary at LIFECORE BIOMEDICAL, INC. DE.

Action: employment will end
Role: Chief Financial Officer and Secretary

Exact text from the filing

Mr. Morberg's separation will be treated as a termination by the Company without Cause subsequent to a Change in Control under that certain Executive Employment Agreement (the "Morberg Employment Agreement"), dated January 19, 2021, between the Company and Mr. Morberg

View on SEC.gov

LIFECORE BIOMEDICAL, INC. DE filing history →

Source: SEC EDGAR

accession 0001005286-24-000128

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.